Indaptus Therapeutics Files S-1 with SEC

TL;DR

Indaptus Therapeutics just filed an S-1. IPO incoming?

AI Summary

Indaptus Therapeutics, Inc. filed an S-1 registration statement with the SEC on December 23, 2024. The company, formerly known as Intec Parent Inc. until April 14, 2021, is incorporated in Delaware and headquartered in New York. This filing indicates a move towards public offering or significant corporate action.

Why It Matters

This S-1 filing signals Indaptus Therapeutics' intention to become a publicly traded company or undergo a significant corporate event requiring SEC registration, impacting potential investors and the biotech market.

Risk Assessment

Risk Level: medium — S-1 filings are often precursors to IPOs or significant financial events, which inherently carry market and execution risks.

Key Numbers

• 333-284026 — SEC File Number (Identifies the specific SEC registration)
• 0001857044 — Central Index Key (Unique identifier for the company in SEC filings)

Key Players & Entities

• Indaptus Therapeutics, Inc. (company) — Registrant
• Intec Parent Inc. (company) — Former company name
• 20210414 (date) — Date of name change
• 20241223 (date) — Filing date
• 3 Columbus Circle 15th Floor New York, NY 10019 (address) — Principal executive offices
• Jeffrey A. Meckler (person) — Chief Executive Officer
• Gary Emmanuel, Esq (person) — Legal counsel

FAQ

Key Financial Figures

• $0.01 — 1,229 shares of common stock, par value $0.01 per share, of Indaptus Therapeutics Inc
• $0.938 — stock on the Nasdaq Capital Market was $0.938 per share. Investing in our securitie
• $1.70 — ely exercisable at an exercise price of $1.70 per share and expire five years from th
• $1 — are of common stock and one warrant was $1.825, resulting in gross proceeds of app
• $3.0 m — ting in gross proceeds of approximately $3.0 million, before deducting placement agent
• $0.5 million — expenses in the amount of approximately $0.5 million. November 2024 Financing On Novembe
• $1.05 — ely exercisable at an exercise price of $1.05 per share and expire five years from th
• $2.13 m — ting in gross proceeds of approximately $2.13 million, before deducting placement agent
• $0.345 million — expenses in the amount of approximately $0.345 million. In connection with the November 2024 f
• $1.3125 — at an exercise price per share equal to $1.3125. The placement agent warrants are exerc
• $2.1 million — ll, the proceeds would be approximately $2.1 million. We currently intend to use the net pro

Filing Documents

• forms-1.htm (S-1) — 370KB
• ex5-1.htm (EX-5.1) — 16KB
• ex23-1.htm (EX-23.1) — 6KB
• ex107.htm (EX-FILING FEES) — 17KB
• ex23-1_001.jpg (GRAPHIC) — 44KB
• ex23-1_002.jpg (GRAPHIC) — 64KB
• ex5-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-051850.txt ( ) — 563KB

RISK FACTORS

RISK FACTORS 4 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 5

USE OF PROCEEDS

USE OF PROCEEDS 6 DIVIDEND POLICY 7 SELLING STOCKHOLDER 8

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 11 PLAN OF DISTRIBUTION 17 LEGAL MATTERS 19 EXPERTS 20 WHERE YOU CAN FIND MORE INFORMATION 21 INCORPORATION BY REFERENCE 22 i ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”). As permitted by the rules and regulations of the SEC, the registration statement filed by us includes additional information not contained in this prospectus. You may read the registration statement and the other reports we file with the SEC at the SEC’s website or its offices described below under the heading “Where You Can Find More Information”. You should rely only on the information contained or incorporated by reference in this prospectus. We have not, and the selling stockholders have not, authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. The distribution of this prospectus and sale of these securities in certain jurisdictions may be restricted by law. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. Persons in possession of this prospectus are required to inform themselves about and observe any such restrictions. The information contained in this prospectus and the documents incorporated by reference in this prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents regardless of the time of delivery of this prospectus when any sale of our securities occurs. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus and the documents incorporated by reference in this prospectus in their entirety, before making an investment decision. You should also read and consider the information in th

View Full Filing

View this S-1 filing on SEC EDGAR